What Is Tesamorelin? Research Evidence & Profile

What Is Tesamorelin (Tesa)?

Tesamorelin (Tesa) is a peptide entry commonly associated with growth-hormone-releasing hormone research contexts. This page identifies the material as Tesamorelin (Tesa), with amino acid count 44; synonyms GRF(1-44) analogue. The Tesamorelin (Tesa) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

24ClinicalTrials.gov query records

121PubMed query records

6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for Tesamorelin (Tesa) is organized around growth-hormone-releasing hormone research, peptide signaling studies, ligand-response analysis, and analytical peptide workflows. For Tesamorelin (Tesa), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
NCT01591902Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®	Phase 4	Terminated	Diabetic Retinopathy, HIV	2018-09-11
NCT00675506Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese	Phase 2	Completed	Abdominal Obesity, Growth Hormone Deficiency	2017-12-13
NCT00257712SMART: Somatotrophics, Memory, and Aging Research Trial	Phase 2	Completed	Aging, Mild Cognitive Impairment	2013-12-19
NCT03375788Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk	Phase 2	Completed	Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat, Fatty Liver	2025-11-20
NCT07481734Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)	Phase 2	Recruiting	Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis	2026-03-19
NCT02012556Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients	Phase 1	Completed	HIV	2013-12-16

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Tesamorelin.

Journal not stated · 2012

PMID 31644039

Selected PubMed record

Tesamorelin.

Nature reviews. Drug discovery · 2011 Feb

PMID 21283099

Selected PubMed record

Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.

The Annals of pharmacotherapy · 2012 Feb

PMID 22298602

Selected PubMed record

Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.

Drugs · 2011 May 28

PMID 21668043

Selected PubMed record

Tesamorelin update.

BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation · 2010 Summer-Fall

PMID 21591600

Selected PubMed record

Tesamorelin, a human growth hormone releasing factor analogue.

Expert opinion on investigational drugs · 2009 Mar

PMID 19243281

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: Tesamorelin (Tesa)
Available Specifications: 2mg, 5mg, 10mg, 20mg
Pack Format: 10 Vials
CAS Number: 218949-48-5
Molecular Formula: C221H366N72O67S
Molecular Weight: 5135.86 g/mol
Amino Acid Count: 44
Sequence: trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2
Synonyms: GRF(1-44) analogue
Physical Form: Lyophilized powder

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: PubChem CID 16137828 · Product form must still be matched to the catalogue and batch record.

Research Tools for Tesamorelin (Tesa)

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

An FDA-approved tesamorelin drug product exists for a specific indication; NOVABIO catalogue material is not an FDA-approved drug.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Tesamorelin (Tesa) Research Summary

Identity

Tesamorelin (Tesa); specifications: 2mg, 5mg, 10mg, 20mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

Evidence

24 registry records and 121 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

An FDA-approved tesamorelin drug product exists for a specific indication; NOVABIO catalogue material is not an FDA-approved drug.

Tesamorelin (Tesa) is represented here by the catalogue identity Tesamorelin (Tesa). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 2mg, 5mg, 10mg, 20mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for Tesamorelin (Tesa) is organized around growth-hormone-releasing hormone research, peptide signaling studies, ligand-response analysis, and analytical peptide workflows. For Tesamorelin (Tesa), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 24 ClinicalTrials.gov records and 121 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, An FDA-approved tesamorelin drug product exists for a specific indication; NOVABIO catalogue material is not an FDA-approved drug. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Tesamorelin (Tesa) FAQ

What is Tesamorelin (Tesa)?

What research records are indexed for Tesamorelin (Tesa)?

The synchronized query returned 24 ClinicalTrials.gov records and 121 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Tesamorelin (Tesa) FDA approved?

An FDA-approved tesamorelin drug product exists for a specific indication; NOVABIO catalogue material is not an FDA-approved drug.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.